Efficacy and tolerability of propiverine in children suffering from overactive bladder - a double-blind, randomised, clinical trial versus oxybutynin and placebo

Batinic, Danka; Muertz, Gerd; Schnabel, Frieder; Gramatté, T; Kirch, Wilhelm

doi:10.1016/s1569-9056(02)80436-5

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[19] in adults with neurogenic conditions. Also in children with non‐neurogenic [12] or neurogenic [10] conditions, this distinct advantage of propiverine over oxybutynin was confirmed. All cited studies consistently reported two to four times greater incidence rates of ADRs for oxybutynin than propiverine.…”

Section: Discussionmentioning

confidence: 86%

“…A more favourable tolerability and safety profile has been reported for propiverine [6], a compound with a dual mode of action, with anticholinergic and calcium‐channel‐modulating effects [7]. In children, propiverine has been extensively investigated, especially in neurogenic [8–10], but also in non‐neurogenic conditions [11,12]. Recently, Marschall‐Kehrel et al.…”

Section: Introductionmentioning

confidence: 99%

“…A more favourable tolerability and safety profile has been reported for propiverine [6], a compound with a dual mode of action, with anticholinergic and calciumchannel-modulating effects [7]. In children, propiverine has been extensively investigated, especially in neurogenic [8][9][10], but also in non-neurogenic conditions [11,12]. Recently, Marschall-Kehrel et al [13] reported that in OAB, propiverine was significantly better than placebo, the first study to show the efficacy of an anticholinergic in children with this condition.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study

Mürtz

Braun²,

Gerhardt³

et al. 2010

BJU International

View full text Add to dashboard Cite

adverse events, adverse drug reactions caused by antimuscarinics and premature treatment termination. RESULTSAt 16 study centres, 621 children aged 5-14 years with UI due to overactive bladder were enrolled. After anticholinergic treatment (437 propiverine, 184 oxybutynin) continence was achieved in 61.6% and 58.7% of the patients after 186 and 259 days, respectively. There were clinically relevant improvements in voiding frequency across treatment groups. Daily doses of propiverine were markedly below the recommendations (0.54 vs 0.8 mg/kg body weight), daily doses of oxybutynin were according to the recommendations (0.31 vs 0.2-0.4 mg/kg body weight) at treatment initiation. There was a significantly more favourable tolerability to propiverine than oxybutynin for the overall rate of adverse events (3.9% vs 16.3%, odds ratio 4.813), adverse drug reactions caused by propiverine or oxybutynin (2.8% vs 9.2%) and premature treatment termination due to adverse drug reactions (1.6% vs 4.4%). CONCLUSIONPropiverine and oxybutynin are effective in children with UI due to overactive bladder. Sufficient treatment periods of at least 2, preferably 3-4, months are the crucial factors for a successful treatment. The tolerability profile of propiverine is better than for oxybutynin. KEYWORDSanticholinergics, children, overactive bladder, oxybutynin, propiverine, urinary incontinence Study Type -Therapy (observational cohort) Level of Evidence 2b

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study

Mürtz

Braun²,

Gerhardt³

et al. 2010

BJU International

View full text Add to dashboard Cite

show abstract

“…Batinic et al [64] compared the efficacy and tolerability of propiverine with that of oxybutynin and placebo in children with OAB. 266 children (propiverine (n = 85) 10 mg b.i.d.…”

Section: Propiverinementioning

confidence: 99%

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Asimakopoulos

Cerruto²,

Popolo³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Objectives: To provide an overview on the efficacy, tolerability, safety and health-related quality of life (HRQoL) of drugs with a mixed action used in the treatment of overactive bladder (OAB). Evidence Acquisition: MEDLINE database and abstract books of the major conferences were searched for relevant publications from 1966 to 2011 and using the key words ‘overactive bladder’, ‘detrusor overactivity’, ‘oxybutynin’, ‘propiverine’, and ‘flavoxate’. Two independent reviewers considered publications for inclusion and extracted relevant data, without performing a meta-analysis. Evidence Synthesis: Old and conflicting data do not support the use of flavoxate, while both propiverine and oxybutynin were found to be more effective than placebo in the treatment of OAB. Propiverine was at least as effective as oxybutynin but with a better tolerability profile even in the pediatric setting. Overall, no serious adverse event for any product was statistically significant compared to placebo. Improvements were seen in HRQoL with treatment by the oxybutynin transdermal delivery system and propiverine extended release. Conclusions: While there is no evidence to suggest the use of flavoxate in the treatment of OAB, both oxybutynin and propiverine appear efficacious and safe. Propiverine shows a better tolerability profile than oxybutynin. Both drugs improve HRQoL of patients affected by OAB. Profiles of each drug and dosage differ and should be considered in making treatment choices.

show abstract

“…Für die Wirksubstanz Propiverin zeigte sich in einer kontrollierten Studie bei 50% der Patienten eine signifikante Reduktion inkontinenter Episoden pro Woche um mehr als 50% [5]. In einer neueren doppelblinden, randomisierten Untersuchung [2] ging zwar die Zahl inkontinenter Episoden unter Therapie mit Propiverin zurück (im Durchschnitt von 11,2 auf 6,4), der Effekt war jedoch gegenüber Placebo nicht signifikant.…”

Section: Tagesstationäres Blasentrainingunclassified

Blasenschulung bei Kindern mit funktioneller Harninkontinenz

Bachmann

Heilenkötter

Janhsen

et al. 2007

Monatsschr Kinderheilkd

View full text Add to dashboard Cite

Efficacy and tolerability of propiverine in children suffering from overactive bladder - a double-blind, randomised, clinical trial versus oxybutynin and placebo

Cited by 6 publications

References 0 publications

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

Blasenschulung bei Kindern mit funktioneller Harninkontinenz

Contact Info

Product

Resources

About